vs
Side-by-side financial comparison of JBG SMITH Properties (JBGS) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
JBG SMITH Properties is the larger business by last-quarter revenue ($127.6M vs $75.5M, roughly 1.7× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -2.5%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -6.3%).
JBG SMITH PropertiesJBGSEarnings & Financial Report
JBG SMITH Properties is a publicly traded real estate investment trust based in Bethesda, Maryland.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
JBGS vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $127.6M | $75.5M |
| Net Profit | $-45.5M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | -47.5% | 22.7% |
| Net Margin | -35.7% | — |
| Revenue YoY | -2.5% | 27.7% |
| Net Profit YoY | 24.0% | — |
| EPS (diluted) | $-0.76 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $127.6M | $75.5M | ||
| Q3 25 | $123.9M | $54.5M | ||
| Q2 25 | $126.5M | $52.4M | ||
| Q1 25 | $120.7M | $46.0M | ||
| Q4 24 | $130.8M | $59.1M | ||
| Q3 24 | $136.0M | $80.5M | ||
| Q2 24 | $135.3M | $47.1M | ||
| Q1 24 | $145.2M | $43.8M |
| Q4 25 | $-45.5M | — | ||
| Q3 25 | $-28.6M | $8.8M | ||
| Q2 25 | $-19.2M | $5.9M | ||
| Q1 25 | $-45.7M | $3.0M | ||
| Q4 24 | $-59.9M | — | ||
| Q3 24 | $-27.0M | $20.3M | ||
| Q2 24 | $-24.4M | $-4.5M | ||
| Q1 24 | $-32.3M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | -47.5% | 22.7% | ||
| Q3 25 | -27.5% | 17.6% | ||
| Q2 25 | -18.4% | 12.7% | ||
| Q1 25 | -44.7% | 8.7% | ||
| Q4 24 | -53.6% | 22.6% | ||
| Q3 24 | -22.4% | 27.4% | ||
| Q2 24 | -24.3% | -4.6% | ||
| Q1 24 | -30.1% | -5.3% |
| Q4 25 | -35.7% | — | ||
| Q3 25 | -23.1% | 16.2% | ||
| Q2 25 | -15.2% | 11.2% | ||
| Q1 25 | -37.9% | 6.5% | ||
| Q4 24 | -45.8% | — | ||
| Q3 24 | -19.8% | 25.2% | ||
| Q2 24 | -18.0% | -9.6% | ||
| Q1 24 | -22.2% | -11.0% |
| Q4 25 | $-0.76 | $0.26 | ||
| Q3 25 | $-0.48 | $0.17 | ||
| Q2 25 | $-0.29 | $0.12 | ||
| Q1 25 | $-0.56 | $0.06 | ||
| Q4 24 | $-0.70 | $0.40 | ||
| Q3 24 | $-0.32 | $0.41 | ||
| Q2 24 | $-0.27 | $-0.09 | ||
| Q1 24 | $-0.36 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $75.3M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $1.2B | $130.3M |
| Total Assets | $4.4B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.3M | $97.5M | ||
| Q3 25 | $64.4M | $94.4M | ||
| Q2 25 | $61.4M | $96.0M | ||
| Q1 25 | $81.3M | $93.2M | ||
| Q4 24 | $145.8M | $101.0M | ||
| Q3 24 | $137.0M | $96.7M | ||
| Q2 24 | $163.5M | $96.8M | ||
| Q1 24 | $220.5M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $1.2B | $130.3M | ||
| Q3 25 | $1.2B | $115.3M | ||
| Q2 25 | $1.3B | $104.7M | ||
| Q1 25 | $1.6B | $97.1M | ||
| Q4 24 | $1.8B | $92.1M | ||
| Q3 24 | $1.9B | $71.1M | ||
| Q2 24 | $2.0B | $48.5M | ||
| Q1 24 | $2.1B | $51.0M |
| Q4 25 | $4.4B | $216.3M | ||
| Q3 25 | $4.4B | $202.9M | ||
| Q2 25 | $4.5B | $194.9M | ||
| Q1 25 | $4.7B | $196.2M | ||
| Q4 24 | $5.0B | $213.3M | ||
| Q3 24 | $5.2B | $220.7M | ||
| Q2 24 | $5.3B | $205.0M | ||
| Q1 24 | $5.4B | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.3M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.3M | $14.4M | ||
| Q3 25 | $8.9M | $9.7M | ||
| Q2 25 | $18.8M | $14.1M | ||
| Q1 25 | $12.9M | $3.6M | ||
| Q4 24 | $129.4M | $15.6M | ||
| Q3 24 | $26.4M | $11.0M | ||
| Q2 24 | $23.8M | $1.0M | ||
| Q1 24 | $37.0M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
